Which Has a Better Risk/Reward Ratio - Citigroup or Cell Genesys? [View article]
The 10 billion market cap for CEGE is not that out of line if their GVAX drug is succesful. That may be a big if, but it would be proof of principal for GVAX in general, which is in clinical trials for two other types of cancer. If it works in one, it will probably work in others.
Which Has a Better Risk/Reward Ratio - Citigroup or Cell Genesys? [View article]